{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260616690184/en/Verastem-Oncology-Doses-First-Patient-in-TARGET-D-201-Phase-2-Registration-Directed-Trial-of-VS-7375-Oral-KRAS-G12D-ONOFF-Inhibitor-for-KRAS-G12D-Mutated-Metastatic-Pancreatic-Cancer", "message": "News view counter 802701 successfully enlarged"}